pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-215 |
Genomic Coordinates | chr1: 220117853 - 220117962 |
Synonyms | MIRN215, miRNA215, mir-215, MIR215 |
Description | Homo sapiens miR-215 stem-loop |
Comment | This human miRNA was predicted by computational methods using conservation with mouse and Fugu rubripes sequences . |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-215-3p | |||||||||||||||||||||
Sequence | 64| UCUGUCAUUUCUUUAGGCCAAUA |86 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | Illumina | |||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | LATS2 | ||||||||||||||||||||
Synonyms | KPM | ||||||||||||||||||||
Description | large tumor suppressor kinase 2 | ||||||||||||||||||||
Transcript | NM_014572 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on LATS2 | |||||||||||||||||||||
3'UTR of LATS2 (miRNA target sites are highlighted) |
>LATS2|NM_014572|3'UTR 1 ATGGGGGCCAGGCACCCCCACCACTCGCTGCCTCCCAGGTCAGGGTCCCGGAGCCGGTGCCCTCACAGGCCAATAGGGAA 81 GCCGAGGGCTGTTTTGTTTTAAATTAGTCCGTCGATTACTTCACTTGAAATTCTGCTCTTCACCAAGAAAACCCAAACAG 161 GACACTTTTGAAAACAGGACTCAGCATCGCTTTCAATAGGCTTTTCAGGACCTTCACTGCATTAAAACAATATTTTTGAA 241 AATTTAGTACAGTTTAGAAAGAGCACTTATTTTGTTTATATCCATTTTTTCTTACTAAATTATAGGGATTAACTTTGACA 321 AATCATGCTGCTGTTATTTTCTACATTTGTATTTTATCCATAGCACTTATTCACATTTAGGAAAAGACATAAAAACTGAA 401 GAACATTGATGAGAAATCTCTGTGCAATAATGTAAAAAAAAAAAAAGATAACACTCTGCTCAATGTCACGGAGACCATTT 481 TATCCACACAATGGTTTTTGTTTTTTATTTTTTCCCATGTTTCAAAATTGTGATATAATGATATAATGTTAAAAGCTGCT 561 TTTTTTGGCTTTTTGCATATCTAGTATAATAGGAAGTGTGAGCAAGGTGATGATGTGGCTGTGATTTCCGACGTCTGGTG 641 TGTGGAGAGTACTGCATGAGCAGAGTTCTTCTATTATAAAATTACCATATCTTGCCATTCACAGCAGGTCCTGTGAATAC 721 GTTTTTACTGAGTGTCTTTAAATGAGGTGTTCTAGACAGTGTGCTGATAATGTATTGTGCGGGTGACCTCTTCGCTATGA 801 TTGTATCTCTTACTGTTTTGTTAAAGAAATGCAGATGTGTAACTGAGAAGTGATTTGTGTGTGTGTCTTGGTTGTGATTG 881 GATTCTTTGGGGGGGGGGAACTGAAACATTTGTCATATACTGAACTTATATACATCAAAAGGGATTAATACAGCGATGCC 961 AAAAAGTTTAATCACGGACACATGTCCGTTTCTGTAGTCCGTATGCTCTTTCATTCTTGGTAGAGCTGGTATGTGGAATG 1041 CCATACCTCTGACCCTACTACTTACCTTTTTACTGACAGACTGCCCACACTGAAAGCTTCAGTGAATGTTCTTAGTCCTG 1121 TTTTCTTCTGTTACTGTCAGGAAACTGAGTGATCTAATGGTTCTCTCACTTTTTTTTTGTTCTTTTAGTGTACTTTGAAG 1201 TATCAAATCTTAACTTGGTTTAAACAATACATATTCCTAACCTTTGTAAAAAAGCAAAGATTCTTCAAAATGACATTGAA 1281 ATAAAAAGTAAGCCATACGTATTTTCTTAGAAGTATAGATGTATGTGCGTGTATACACACACACACACACACACAGAGAT 1361 AAACACAATATTCCTTATTTCAAATTAGTATGATTCCTATTTAAAGTGATTTATATTTGAGTAAAAAGTTCAATTCTTTT 1441 TTGCTTTTTAAAAAATCTGATGCTTCATAATTTTCATTATATTATTCCACATATTTTTCCTTGAAGTTCTTAGCATAATG 1521 TATCCATTACTTAGTATATATCTAGGCAACAACACTTAGAAGTTTATCAGTGTTTAAACTAAAAAAATAAAGATTCCTGT 1601 GTACTGGTTTACATTTGTGTGAGTGGCATACTCAAGTCTGCTGTGCCTGTCGTCGTGACTGTCAGTATTCTCGCTATTTT 1681 ATAGTCGTGCCATGTTGTTACTCACAGCGCTCTGACATACTTTCATGTGGTAGGTTCTTTCTCAGGAACTCAGTTTAACT 1761 ATTATTTATTGATATATCATTACCTTTGAAAAGCTTCTACTGGCACAATTTATTATTAAAATTTTGAATCCAAAAAAAAA 1841 AAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HCT116 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in ERX177602. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_2_4
... - Krell J; Stebbing J; Carissimi C; Dabrowska et al., 2016, Genome research. |
Article |
- Krell J; Stebbing J; Carissimi C; Dabrowska et al. - Genome research, 2016
DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2's association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.
LinkOut: [PMID: 26701625]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Prostate Tissue |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760638. RNA binding protein: AGO2. Condition:AGO-CLIP-PC3-miR148
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000382592.4 | 3UTR | CCAUACCUCUGACCCUACUACUUACCUUUUUACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
96 hsa-miR-215-3p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT058509 | TEAD1 | TEA domain transcription factor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT445625 | TMEM50A | transmembrane protein 50A | ![]() |
![]() |
2 | 2 | ||||||
MIRT449286 | RPP14 | ribonuclease P/MRP subunit p14 | ![]() |
![]() |
2 | 2 | ||||||
MIRT456702 | LDB1 | LIM domain binding 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT467723 | SLC38A1 | solute carrier family 38 member 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT474253 | LATS2 | large tumor suppressor kinase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT481811 | AP4E1 | adaptor related protein complex 4 epsilon 1 subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT491969 | USP37 | ubiquitin specific peptidase 37 | ![]() |
![]() |
2 | 2 | ||||||
MIRT513203 | RFT1 | RFT1 homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT532737 | CMTM6 | CKLF like MARVEL transmembrane domain containing 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT535706 | NAA50 | N(alpha)-acetyltransferase 50, NatE catalytic subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT536138 | MAPK14 | mitogen-activated protein kinase 14 | ![]() |
![]() |
2 | 2 | ||||||
MIRT536463 | KLF12 | Kruppel like factor 12 | ![]() |
![]() |
2 | 4 | ||||||
MIRT552615 | ZBTB8A | zinc finger and BTB domain containing 8A | ![]() |
![]() |
2 | 2 | ||||||
MIRT554011 | SPIRE1 | spire type actin nucleation factor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT563259 | SLC29A1 | solute carrier family 29 member 1 (Augustine blood group) | ![]() |
![]() |
2 | 2 | ||||||
MIRT571054 | POLQ | DNA polymerase theta | ![]() |
![]() |
2 | 4 | ||||||
MIRT573556 | TMEM120B | transmembrane protein 120B | ![]() |
![]() |
2 | 2 | ||||||
MIRT573772 | PRKAG1 | protein kinase AMP-activated non-catalytic subunit gamma 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT575328 | Fbxo6 | F-box protein 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT575497 | Sept3 | septin 3 | ![]() |
![]() |
2 | 5 | ||||||
MIRT607051 | IDS | iduronate 2-sulfatase | ![]() |
![]() |
2 | 2 | ||||||
MIRT607070 | POM121L7 | POM121 transmembrane nucleoporin like 7 pseudogene | ![]() |
![]() |
2 | 2 | ||||||
MIRT607497 | HEBP2 | heme binding protein 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT607799 | RHBDL2 | rhomboid like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT610832 | COL9A1 | collagen type IX alpha 1 chain | ![]() |
![]() |
2 | 2 | ||||||
MIRT616853 | DSG2 | desmoglein 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT617154 | C18orf42 | A-kinase anchor inhibitor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT620823 | MKI67IP | nucleolar protein interacting with the FHA domain of MKI67 | ![]() |
1 | 1 | |||||||
MIRT625698 | OPTN | optineurin | ![]() |
![]() |
2 | 2 | ||||||
MIRT628082 | KAT7 | lysine acetyltransferase 7 | ![]() |
![]() |
2 | 2 | ||||||
MIRT633540 | PGBD5 | piggyBac transposable element derived 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT634343 | SGOL1 | shugoshin 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT634605 | KIAA1919 | major facilitator superfamily domain containing 4B | ![]() |
![]() |
2 | 2 | ||||||
MIRT636759 | SLC16A5 | solute carrier family 16 member 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT637044 | SEPT3 | septin 3 | ![]() |
![]() |
2 | 7 | ||||||
MIRT637213 | TRUB2 | TruB pseudouridine synthase family member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT639634 | ZSCAN23 | zinc finger and SCAN domain containing 23 | ![]() |
![]() |
2 | 2 | ||||||
MIRT640818 | GPR107 | G protein-coupled receptor 107 | ![]() |
![]() |
2 | 2 | ||||||
MIRT641033 | PITPNB | phosphatidylinositol transfer protein beta | ![]() |
![]() |
2 | 2 | ||||||
MIRT641545 | MOCOS | molybdenum cofactor sulfurase | ![]() |
![]() |
2 | 2 | ||||||
MIRT642091 | FBXL2 | F-box and leucine rich repeat protein 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT645528 | ZWINT | ZW10 interacting kinetochore protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT647017 | ADCY2 | adenylate cyclase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT648044 | FADS6 | fatty acid desaturase 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT648514 | PIGG | phosphatidylinositol glycan anchor biosynthesis class G | ![]() |
![]() |
2 | 2 | ||||||
MIRT648869 | ABCA6 | ATP binding cassette subfamily A member 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT656722 | LMLN | leishmanolysin like peptidase | ![]() |
![]() |
2 | 2 | ||||||
MIRT658260 | FAXC | failed axon connections homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT659063 | DEPTOR | DEP domain containing MTOR interacting protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT659364 | CRISPLD2 | cysteine rich secretory protein LCCL domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT660318 | BDP1 | B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB | ![]() |
![]() |
2 | 2 | ||||||
MIRT663345 | ZNF74 | zinc finger protein 74 | ![]() |
![]() |
2 | 2 | ||||||
MIRT663526 | MASTL | microtubule associated serine/threonine kinase like | ![]() |
![]() |
2 | 2 | ||||||
MIRT663975 | ZNF786 | zinc finger protein 786 | ![]() |
![]() |
2 | 2 | ||||||
MIRT664354 | C16orf45 | chromosome 16 open reading frame 45 | ![]() |
![]() |
2 | 2 | ||||||
MIRT664473 | ZYG11B | zyg-11 family member B, cell cycle regulator | ![]() |
![]() |
2 | 2 | ||||||
MIRT664975 | TDRD1 | tudor domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT665488 | VPS53 | VPS53, GARP complex subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT667758 | KDELR1 | KDEL endoplasmic reticulum protein retention receptor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT669552 | ALG14 | ALG14, UDP-N-acetylglucosaminyltransferase subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT670183 | CCDC142 | coiled-coil domain containing 142 | ![]() |
![]() |
2 | 2 | ||||||
MIRT671342 | FAM71F2 | family with sequence similarity 71 member F2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT671873 | ZNF429 | zinc finger protein 429 | ![]() |
![]() |
2 | 2 | ||||||
MIRT672018 | PXMP4 | peroxisomal membrane protein 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT672068 | KIAA0930 | KIAA0930 | ![]() |
![]() |
2 | 2 | ||||||
MIRT672551 | BRMS1L | breast cancer metastasis-suppressor 1 like | ![]() |
![]() |
2 | 2 | ||||||
MIRT672849 | ICOSLG | inducible T-cell costimulator ligand | ![]() |
![]() |
2 | 2 | ||||||
MIRT672988 | KBTBD6 | kelch repeat and BTB domain containing 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT673088 | AK1 | adenylate kinase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT673578 | KDELC2 | KDEL motif containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT674582 | SLC35B4 | solute carrier family 35 member B4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT674999 | STRN3 | striatin 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT675596 | ZNF106 | zinc finger protein 106 | ![]() |
![]() |
2 | 2 | ||||||
MIRT675778 | YIPF4 | Yip1 domain family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT676029 | C9orf69 | transmembrane protein 250 | ![]() |
![]() |
2 | 2 | ||||||
MIRT679015 | MTMR10 | myotubularin related protein 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT679169 | PSMB2 | proteasome subunit beta 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT687413 | NRIP1 | nuclear receptor interacting protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT688038 | GNE | glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT691644 | SLC43A3 | solute carrier family 43 member 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT695630 | SLC26A2 | solute carrier family 26 member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT697562 | ZBTB10 | zinc finger and BTB domain containing 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT699153 | SMC1A | structural maintenance of chromosomes 1A | ![]() |
![]() |
2 | 2 | ||||||
MIRT699683 | SFMBT2 | Scm like with four mbt domains 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT702177 | LYRM4 | LYR motif containing 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT706217 | ACOT9 | acyl-CoA thioesterase 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT711243 | TRAT1 | T-cell receptor associated transmembrane adaptor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT712343 | NLN | neurolysin | ![]() |
![]() |
2 | 2 | ||||||
MIRT716574 | HOPX | HOP homeobox | ![]() |
![]() |
2 | 2 | ||||||
MIRT717443 | TENM1 | teneurin transmembrane protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT717759 | KCNRG | potassium channel regulator | ![]() |
![]() |
2 | 2 | ||||||
MIRT717945 | TUBD1 | tubulin delta 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT718343 | PURA | purine rich element binding protein A | ![]() |
![]() |
2 | 2 | ||||||
MIRT718773 | ABHD15 | abhydrolase domain containing 15 | ![]() |
![]() |
2 | 2 | ||||||
MIRT737073 | FOXM1 | forkhead box M1 | ![]() |
![]() |
2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|